CRBU

Caribou Biosciences, Inc. (CRBU) | Rumor.io

Caribou Biosciences

CRBU

Attention (50-day avg)0%

Attention rank (50-day avg)#1,490

Bullish sentiment (50-day avg)69%

Price to earnings ratio-0.78

Market capitalization131.9M

Earnings per share-1.08

Dividend yield (TTM)—

Revenue (annual)11.2M

Net income (annual)-148.1M

Social

What share of all stock conversation is about CRBU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 13

Caribou Biosciences, Inc. reported Q2 2026 earnings, with a decrease in cash burn rate and operating expenses.
The company's CAR-T therapy, CB-011, showed promising results with a 92% overall response rate and 91% complete response rate in a small cohort of 12 patients.
The potential of CB-011 to confirm durability and attract a partner or investor is seen as a key factor in the company's future value.

Generated by AI

Sentiment

Of the messages about CRBU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	87.84% +22.91	86.6% +18.07
Bearish	—	0% 0	12.16% -22.91	13.4% -18.07

Bullish· Nov 5

Strong data from Caribou Biosciences (CRBU) make it a potential acquisition target for large oncology players, particularly due to its CRISPR-based manufacturing platform and dual hematologic oncology indications.
Citi raised its price target for CRBU to $8, citing compelling ANTLER data that de-risks the program for pivotal trials expected in H1 2026.
CRBU's shorts are getting exposed, with the stock experiencing significant gains and potential for further upside, with some investors expecting a first 230% gain followed by another 250% gain next year.

Bearish· Nov 3

The company's stock price has made an unjustified move, prompting some to take action by shorting the stock.
The company's recent activity, including a shelf offering for $300M, may indicate that they will sell into any rally, potentially leading to a further decline in the stock price.
The stock's history of rapid price increases followed by significant declines suggests that it may be a pump and dump scheme, with the price likely to fall back down through $6.00.

Generated by AI

Topics

Of the messages about CRBU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.64%
Analysts	—	0%	0%	12.51%
Technical Analysis	—	0%	0%	9.17%
Controversies	—	0%	0%	0.22%
Macro	—	0%	0%	5.98%
Earnings	—	0%	0%	2.49%

Analysts· Aug 17

SVB Leerink initiates coverage on Caribou Biosciences with an Outperform rating and a $32 price target.
BofA Securities initiates coverage on Caribou Biosciences with a Buy rating and a $30 price target.
Citigroup initiates coverage on Caribou Biosciences with a Neutral rating and a $27 price target.

Announcements· Mar 31

Caribou Biosciences, Inc. (CRBU) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, an allogeneic anti-BCMA CAR-T cell therapy, for the treatment of relapsed or refractory multiple myeloma.
The RMAT designation is a high-quality regulatory catalyst, signaling FDA support and potential acceleration pathway for CB-011, which has shown promising results in Phase 1 data, including a 92% overall response rate and 75% complete response rate in BCMA-naïve patients.
The FDA designation is a significant milestone for Caribou Biosciences, and the company's stock surged by 14.5% after the announcement, with the possibility of sector rotation and risk management being important considerations for investors.

Technical Analysis· Jul 7

CRBU has shown strong support at $4.10, holding this level 10 times over a 3+ month period.
The stock is currently at a 45% gap and is near a secondary resistance level, making it a potentially good stock for day trades.
CRBU has broken above VWAP and is looking to break through the $7 resistance level for a potential breakout.

Generated by AI

Community

Of the messages about CRBU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	89.74%	75.62%
Newcomers	0%	0%	10.26%	24.38%

Regulars· Nov 3

Caribou Biosciences' off-the-shelf CAR-T therapy has shown complete and durable remissions in patients with advanced B-cell lymphoma, comparable to benchmarks set by currently approved therapies.
The company's allogeneic CAR-T cell therapy candidate, vispacabtagene regedleucel, has demonstrated efficacy and durability comparable to autologous CAR-T cell therapies, with a 92% overall response rate and 75% complete response rate in a Phase 1 trial.
Caribou Biosciences' positive data from its Phase 1 trials, including the ANTLER phase 1 trial and the CaMMouflage Phase 1 trial, has confirmed the efficacy and durability of its allogeneic CAR-T cell therapies, with the longest responding patient completing the 2-year follow-up period.

Newcomers· Nov 4

Newcomers are focused on the positive Phase 1 data for Caribou Biosciences' allogeneic CAR T therapies, which has drawn institutional interest and led to a surge in trading volume.
The stock's downward reaction is attributed to the strong and cost-efficient nature of the Phase 1 study's results, which may have been perceived as a threat to the company's allogeneic CAR-T therapy.
Citi has raised its price target for CRBU to $8, citing the stellar Phase 1 data, with a 100% overall response rate and durable responses in the allogeneic CAR-T therapy.

Generated by AI

The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

15d agoYahoo Finance

BofA Adjusts Price Target on Caribou Biosciences to $5 From $6

Caribou Biosciences (CRBU) has an average rating of buy and mean price target of $11.86, according t

1mo agoYahoo Finance

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

1mo agoInvesting.com

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1mo agoYahoo Finance

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patient

1mo agoYahoo Finance

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.

2mo agoYahoo Finance

Also Discussed

Investors talking about CRBU also mention

#	Name	Attention
1	Beam Therapeutics IncBEAM	0.02%+0.02
2	Intellia Therapeutics, Inc.NTLA	0%+0
3	Editas Medicine, Inc.EDIT	0%+0
4	Prime Medicine, Inc.PRME	0%-0.01
5	CRISPR Therapeutics AGCRSP	0%0
6	VERV - Verve Therapeutics, Inc.	——
7	Century Therapeutics IncIPSC	0%0
8	Precision BioSciences, Inc.DTIL	0%new
9	ALX Oncology Holdings Inc.ALXO	0%0
10	EXAI - Exscientia plc	——

Caribou Biosciences, Inc.

Healthcare
Biotechnology

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform. The company works on off-the-shelf CAR-T and CAR-NK therapies designed to support precise cell engineering for difficult-to-treat diseases. Its current pipeline centers on hematologic malignancies and autoimmune disorders, with programs that include anti-CD19, anti-BCMA, and anti-CD371 cell therapies in clinical development. Caribou Biosciences also applies its gene-editing technology to advance broader research and therapeutic applications in biotechnology. Headquartered in Berkeley, California, the company operates as a single business segment centered on next-generation cell therapy development.

Website

Location

2929 7th Street

Berkeley, CA, 94710

United States

Social

What share of all stock conversation is about CRBU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 13

Caribou Biosciences, Inc. reported Q2 2026 earnings, with a decrease in cash burn rate and operating expenses.
The company's CAR-T therapy, CB-011, showed promising results with a 92% overall response rate and 91% complete response rate in a small cohort of 12 patients.
The potential of CB-011 to confirm durability and attract a partner or investor is seen as a key factor in the company's future value.

Generated by AI

Sentiment

Of the messages about CRBU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	87.84% +22.91	86.6% +18.07
Bearish	—	0% 0	12.16% -22.91	13.4% -18.07

Bullish· Nov 5

Strong data from Caribou Biosciences (CRBU) make it a potential acquisition target for large oncology players, particularly due to its CRISPR-based manufacturing platform and dual hematologic oncology indications.
Citi raised its price target for CRBU to $8, citing compelling ANTLER data that de-risks the program for pivotal trials expected in H1 2026.
CRBU's shorts are getting exposed, with the stock experiencing significant gains and potential for further upside, with some investors expecting a first 230% gain followed by another 250% gain next year.

Bearish· Nov 3

The company's stock price has made an unjustified move, prompting some to take action by shorting the stock.
The company's recent activity, including a shelf offering for $300M, may indicate that they will sell into any rally, potentially leading to a further decline in the stock price.
The stock's history of rapid price increases followed by significant declines suggests that it may be a pump and dump scheme, with the price likely to fall back down through $6.00.

Generated by AI

Topics

Of the messages about CRBU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.64%
Analysts	—	0%	0%	12.51%
Technical Analysis	—	0%	0%	9.17%
Controversies	—	0%	0%	0.22%
Macro	—	0%	0%	5.98%
Earnings	—	0%	0%	2.49%

Analysts· Aug 17

SVB Leerink initiates coverage on Caribou Biosciences with an Outperform rating and a $32 price target.
BofA Securities initiates coverage on Caribou Biosciences with a Buy rating and a $30 price target.
Citigroup initiates coverage on Caribou Biosciences with a Neutral rating and a $27 price target.

Announcements· Mar 31

Caribou Biosciences, Inc. (CRBU) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, an allogeneic anti-BCMA CAR-T cell therapy, for the treatment of relapsed or refractory multiple myeloma.
The RMAT designation is a high-quality regulatory catalyst, signaling FDA support and potential acceleration pathway for CB-011, which has shown promising results in Phase 1 data, including a 92% overall response rate and 75% complete response rate in BCMA-naïve patients.
The FDA designation is a significant milestone for Caribou Biosciences, and the company's stock surged by 14.5% after the announcement, with the possibility of sector rotation and risk management being important considerations for investors.

Technical Analysis· Jul 7

CRBU has shown strong support at $4.10, holding this level 10 times over a 3+ month period.
The stock is currently at a 45% gap and is near a secondary resistance level, making it a potentially good stock for day trades.
CRBU has broken above VWAP and is looking to break through the $7 resistance level for a potential breakout.

Generated by AI

Community

Of the messages about CRBU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	89.74%	75.62%
Newcomers	0%	0%	10.26%	24.38%

Regulars· Nov 3

Caribou Biosciences' off-the-shelf CAR-T therapy has shown complete and durable remissions in patients with advanced B-cell lymphoma, comparable to benchmarks set by currently approved therapies.
The company's allogeneic CAR-T cell therapy candidate, vispacabtagene regedleucel, has demonstrated efficacy and durability comparable to autologous CAR-T cell therapies, with a 92% overall response rate and 75% complete response rate in a Phase 1 trial.
Caribou Biosciences' positive data from its Phase 1 trials, including the ANTLER phase 1 trial and the CaMMouflage Phase 1 trial, has confirmed the efficacy and durability of its allogeneic CAR-T cell therapies, with the longest responding patient completing the 2-year follow-up period.

Newcomers· Nov 4

Newcomers are focused on the positive Phase 1 data for Caribou Biosciences' allogeneic CAR T therapies, which has drawn institutional interest and led to a surge in trading volume.
The stock's downward reaction is attributed to the strong and cost-efficient nature of the Phase 1 study's results, which may have been perceived as a threat to the company's allogeneic CAR-T therapy.
Citi has raised its price target for CRBU to $8, citing the stellar Phase 1 data, with a 100% overall response rate and durable responses in the allogeneic CAR-T therapy.

Generated by AI

Caribou Biosciences

Social

Aug 13

Bullish· Nov 5

Bearish· Nov 3

Analysts· Aug 17

Announcements· Mar 31

Technical Analysis· Jul 7

Regulars· Nov 3

Newcomers· Nov 4

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BofA Adjusts Price Target on Caribou Biosciences to $5 From $6

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Also Discussed

Caribou Biosciences, Inc.

Company Information

Location

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BofA Adjusts Price Target on Caribou Biosciences to $5 From $6

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Also Discussed

Social

Aug 13

Bullish· Nov 5

Bearish· Nov 3

Analysts· Aug 17

Announcements· Mar 31

Technical Analysis· Jul 7

Regulars· Nov 3

Newcomers· Nov 4